Boston Scientific Gets Early Nod For Next Gen S-ICD
This article was originally published in The Gray Sheet
Executive Summary
Boston's Emblem S-ICD upgrade was approved by FDA and in Europe earlier than anticipated.
You may also be interested in...
Careful Scrutiny Of Leadless Pacemaker Adverse Events Urged By FDA Panel
As the agency prepares for PMA submissions from Medtronic and St. Jude for first-to-market leadless pacemakers, its advisory panel emphasized the importance of large and long post-approval studies that single out individual adverse event types for measurement.
Boston Scientific Will Lean On Quadripolar, S-ICD To Revive Sagging U.S. CRM Sales
Boston Scientific reported disappointing first-quarter results for its cardiac rhythm management division, mostly due to price erosion in the U.S and the lack of a quadripolar CRT-D device. But the firm argues that the new S-ICD and forthcoming quadripolar CRT-D products may help turn the business around soon.
Boston Scientific Buys Cameron Health For First Subcutaneous ICD
Deal includes $150 million up front, but is worth up to $1.35 billion with potential milestone payments.